# ReVision Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revision-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: https://www.revisiontx.com/
- Total disclosed funding: $0.5M
- Latest round: Series B (Dec 19, 2011)
- Investors on record: 1

## About

ReVision Therapeutics, Inc. is focused on developing innovative medicines aimed at preserving vision. Their work targets retinal disorders and age-related vision loss through advanced drug formulations and delivery mechanisms.Founded in 2010 and headquartered in San Diego, US, ReVision Therapeutics, Inc. specializes in therapies for retinal disorders. The company raised USD 0.50 million in Series B funding on December 19, 2011, from returning investor Avalon Ventures, resulting in a post-money valuation of USD 15.42 mn. The firm has completed a total of 1 deal to date.ReVision Therapeutics specializes in innovative medicines designed to protect and preserve vision, focusing on therapies for retinal disorders and age-related vision loss. Their flagship products cater to healthcare providers, targeting degenerative eye diseases, and are distributed primarily in North America and Europe to ophthalmologists, hospitals, and specialty clinics.Revenue generation for ReVision Therapeutics is based on B2B transactions with healthcare providers, selling therapies to clinics and hospitals. Pricing models for their flagship products include one-time purchases and subscription arrangements, with revenue streams enhanced through collaborations with research institutions and pharmaceutical partners.The Series B funding raised in December 2011 will support ReVision Therapeutics' strategy for future growth, which includes developing new therapies for retinal disorders. The company aims to expand its market reach beyond North America and Europe, targeting additional regions by 2023 to enhance access to their products. With a current valuation of USD 15.42 mn, the firm plans to utilize this funding to advance its product pipeline and strengthen partnerships within the ocular health market.

## Funding rounds

- Series B, Dec 19, 2011, $0.5M — Avalon Ventures

## Investors

- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series B